Close
CDMO Safety Testing 2026
Novotech

Clinical Trials

Phesi data show clinical trial suspensions continue to rise as COVID-19 impact on development persists

Analysis from Phesi shows the impact of COVID-19 on clinical development is continuing to mount, with many clinical trial sites unable to bounce back following suspension in March and April 2020. Phesiโ€™s previous analysis in May 2020 found that...

Merck announces positive results phase 3 trials of gefapixant 45 mg twice daily in patients with refractory or unexplained chronic cough

Merck, known as MSD outside the United States and Canada, has announced the results from two pivotal phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist,...

Sharp launches Clinventory Inventory Management System (IMS) for clinical trials

Sharp - part of UDG Healthcare plc, a global leader in contract packaging clinical supply services, has launched a new Inventory Management System (IMS) to support clinical trial sponsors in managing inventory and supplies. The new system - named Clinventory...

Sinovac Biotech’s COVID-19 vaccine enters phase 3 trial globally

A COVID-19 vaccine candidate developed by Beijing-based Sinovac Life Sciences Corp has obtained preliminary approval in Bangladesh for entering phase III clinical trials, the company. "Our vaccine has received approval from a national drug research council in Bangladesh and is...

Bharat Biotech gets approval to conduct phase 2 trials of COVID-19 vaccine Covaxin

Hyderabad-based Bharat Biotech has received approval to conduct phase II trials of its COVID-19 vaccine Covaxin from September 7. The Directorate General of Health Service said in a statement: "This is to inform you that the subject proposal was examined...

Early trials find Russia’s Sputnik V safe, volunteers develop coronavirus antibodies within 3 weeks

Much buzz was created around the world when Russia claimed to have approved the first COVID-19 vaccine around the world, for public use. Experts and researchers from around the world questioned the efficacy and safety of the vaccine, dubbed...

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

Sanofi and GSK today started the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofiโ€™s seasonal influenza vaccines with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป